Navigation Links
Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film
Date:5/2/2011

JERSEY CITY, N.J., May 2, 2011 /PRNewswire/ -- Aoxing Pharmaceutical (NYSE Amex: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, announced that its operating subsidiary in China, Hebei Aoxing Pharmaceutical Group Company, has been granted a patent by the State Intellectual Property Office of The People's Republic of China for naloxone sublingual film.   The Chinese patent, ZL2005.1.0125279.7, covers a unique sublingual film formulation of naloxone that can be dissolved rapidly under the tongue.  

Naloxone is an opioid receptor antagonist that is used clinically to relieve life-threatening depression of the central nervous system and respiratory system, caused by overdose of morphine and other opioids.  It may also be used as an adjunctive therapy to increase blood pressure in the treatment of septic shocks.  It is most commonly injected intravenously for fastest action.  Oral delivery is used in emergent care due to slow and poor absorption.  However, injection is inconvenient and requires a nurse to administer it.  The sublingual film developed by Aoxing Pharma can be dissolved in under 30 seconds and allows the drug to diffuse into the blood through tissues under the tongue.  The rapid and more efficient absorption of the formulation makes it a convenient alternative to injection.

Mr. Zhenjiang Yue, Chairman and CEO of Aoxing Pharma, commented, "I would like to thank our research and development team for its dedication in driving forward this unique product, now proprietary to Aoxing.  The convenient administration of naloxone could win critical time in emergency and save lives. We look forward to developing this new therapeutic delivery method for this important market."  

About Aoxing Pharmaceutical Company, Inc.

Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the Chinese State Food and Drug Administration (SFDA). It has joint venture collaboration with Johnson Matthey Plc to produce and market narcotics and neurological drugs in China. It also has strategic alliance partnerships with QRxPharma, Phoenix PharmaLabs, Inc. and American Oriental Bioengineering, Inc. For more information, please visit: www.aoxingpharma.com.

Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc.

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and the Company's actual results may differ materially due to a number of factors, many of which are beyond its ability to predict or control, including, among many others, the Company's ability to commercialize on the patent subject of this press release, its ability to develop new therapeutic delivery methods, to complete GMP certification of the workshops, obtain process approvals, develop the product line as and when anticipated. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by the Company. The Company operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. These forward-looking statements are based on the Company's current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments affecting the Company will be those anticipated by the Company. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

CONTACT:

Aoxing Pharmaceutical Company:
Bob Ai
Chief Financial Officer
646-367-1747
investor.relations@aoxingpharma.com

Investor Relations:
The Trout Group
Brian Korb
646-378-2923
bkorb@troutgroup.com


'/>"/>
SOURCE Aoxing Pharmaceutical Company, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
2. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Dr. Vivek Ahuja , ... Ste phen Schmidt ... of cloud-based software solutions for life sciences, today announced key new ... wealth of insight to a growing business.  This will bolster the ... George Phillips joined ArisGlobal in the position of Vice President ...
(Date:4/28/2016)... MARLTON, N.J. , April 28, 2016   ... solutions, today announced that leading IT market research and ... Player " in the IDC MarketScape: Worldwide Pharmaceutical Track ... March 2016).  The report provides an assessment of the ... pharmaceutical track and trace software market. Logo ...
(Date:4/28/2016)... TapImmune,Inc. (TPIV), a clinical-stage ... gene-based immunotherapeutics and vaccines for the treatment of cancer & ... 3rd Annual Growth Capital Expo to be held ... Caesars Palace in Las Vegas, Nevada.  The Company presentation ... th by Dr. John N. Bonfiglio a ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... ... In 2011, TIME magazine named Herr the “Leader of the Bionic Age”, because ... physiology with electromechanics. He continues that work as Director of the Biomechatronics research group ... a leader in the field of prosthetic devices. , After a blizzard during a ...
(Date:4/28/2016)... San Antonio, Texas (PRWEB) , ... April 28, 2016 , ... ... counseling, recently opened its newest office in San Antonio – its San Antonio West ... over 10 years in medical device sales. The grand opening of Amada San Antonio ...
(Date:4/28/2016)... MA (PRWEB) , ... April 28, 2016 , ... A ... were typical among 18 states studied, the Workers Compensation Research Institute (WCRI) ... The WCRI study, CompScope™ Benchmarks for Kentucky, 16th Edition , found that indemnity ...
(Date:4/28/2016)... WASHINGTON D.C. (PRWEB) , ... April 28, 2016 ... ... be receiving state-specific Pharmacy Discount Cards in the mail from USA Medical Prescription ... in each state. , Each mailed package will include a ready-to-use, ...
(Date:4/28/2016)... , ... April 28, 2016 , ... Boston Laser is ... and Drug Administration (FDA). The treatment consists of the application of Riboflavin, a vitamin, ... collagen fibers which in turn strengthens the cornea to slow the progression of keratoconus. ...
Breaking Medicine News(10 mins):